현재 위치
Home
Biosimilar, Bio-better & Antibody Engineering Symposium - 좌장: 문경덕(한화), 김세호(녹십자)
Overview of Biosimilar Business
-
- 발행기관
- 한국생물공학회 바로가기
-
- 간행물
- 한국생물공학회 학술대회 바로가기
-
- 통권
- 2010 춘계학술대회 및 국제심포지움 (2010.04)바로가기
-
- 페이지
- pp.63-63
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A119194
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- There has been a lot of attention and subsequent business activities around biosimilar in Korea during the past a couple of years. Not only some sizeable Korean pharmaceutical companies but some new players in pharmaceutical/biopharmaceutical sectors took a step in developing biosimilar products and particularly some notable companies widely covered by press have apparently shown aggressive moves to bring their products beyond Korean market. On government side, relatively big financial support was granted to a group of companies developing biosimilar products under the name of "SMART Project". Following these movements, various endeavors by government sector including the foundation of fund to support bio-business are expected to be observed in near future. All these activities around biosimilar business is based on a fundamental assumption that biosimilar could become a national platform as a future growth engine. At this point of time when unprecedented amount of investment is being put into biosimilar business, we need to answer some critical questions to project outlook of biosimilar and ultimately to figure out strategy and action plans to win this game
• Is there going to be a market forbiosimilar and then how big will it be?
• What are drivers and risks of biosimilar business?
• Who are current players and where are they playing in terms of value chain & geography
and what are their core competencies?
• What would be the key success factors in biosimilar business from Korean company’s
perspective?
• What are the effective strategy, commercial model, roles & responsibilities and action plans
for each of Korean companies and Korean government?
IMS Korea will elaborate on current market status, key drivers & risks, difference between
chemical generic & biosimilar and points to be considered by Korean companies. And then
IMS will provide some feasible high-level strategic options for biosimlar commercialization.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
- 설립연도
- 1984
- 분야
- 공학>생물공학
- 소개
- 이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다 1. 생물공학 분야의 발전을 위한 연구 협력 2. 생물공학의 실용화를 촉진시키기 위한 산학 협동 3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최 4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간 5. 생물공학 발전을 위한 정책 건의 6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동
간행물
-
- 간행물명
- 한국생물공학회 학술대회
- 간기
- 반년간
- 수록기간
- 1985~2013
- 십진분류
- KDC 476 DDC 576
이 권호 내 다른 논문 / 한국생물공학회 학술대회 2010 춘계학술대회 및 국제심포지움
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.